News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ChiRhoClin Release: ChiRhoStim (Human Secretin For Injection) ChiRhoClin Approved Labeling Update And 5-Year Shelf Life Approval



7/25/2017 10:16:50 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

BURTONSVILLE, Md., July 25, 2017 /PRNewswire/ -- ChiRhoClin, Inc. is pleased to notify the medical community that ChiRhoStim® (Human Secretin for Injection) has received FDA approval, updating its package insert. There are two significant changes to the package insert. The first change eliminates the need to inject a test dose prior to administering ChiRhoStim®. The second significant change is the removal of the contraindication section. The benefit for patients experiencing an acute pancreatitis episode is that they can be administered ChiRhoStim® for pancreatic evaluation. These two changes to the package labeling may shorten procedure time and patient treatment. In addition, an extended 5-year shelf life of ChiRhoStim® was approved. This shelf life extension of the product stability will provide a steady stream of Secretin for the future.

ChiRhoStim® is an orphan drug product that aids in the diagnoses of pancreatic cancer and pancreatic exocrine dysfunction. ChiRhoStim® is approved for pancreatic function testing, facilitating cannulation during ERCP, and Gastrinoma testing. In addition, secretions of the pancreatic fluid after secretin stimulation can be used in situ for imaging modalities such as MRCP, CT, and EUS.

Skip Purich, C.O.O., said "These improvements to our product shelf life and updated labeling will assist the medical community in shortening Gastroenterology and Radiology procedure times. As well as not delaying diagnostic testing such as secretin stimulated MRCP (SMRCP) or function testing while a patient is suffering from acute pancreatitis."

ChiRhoClin, Inc., a Maryland based family run corporation founded in 1991 by Dr. Edward D. Purich, is a research and development oriented pharmaceutical company focused on developing orphan drug products for the gastrointestinal and radiological community. Our emphasis is to develop orphan drug products that will diagnose and treat pancreatic gastrointestinal diseases and encourage research in the pancreatic area through our small pancreatic grant program.

If you would like more information on ChiRhoStim® (Human Secretin for Injection), please visit www.ChiRhoStim.com or call 1-877-272-4888.

View original content:http://www.prnewswire.com/news-releases/chirhostim-human-secretin-for-injection-fda-approved-labeling-update-and-5-year-shelf-life-approval-300493201.html

SOURCE ChiRhoClin, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES